Dendreon In Trouble
Dendreon Corporation (NASDAQ: DNDN) is in trouble. That is what the performance is telling investors. The maker of Provenge as a late-stage prostate cancer treatment has three issues working against ...Read Full Story »
Posts related to ‘prostate cancer treatments’
Read Full Story »
-
Categories:
- 24/7 Wall St. Wire (9929)
- Accounting (512)
- Active Trader (4402)
- Aerospace & Defense (230)
- Alternative Energy (1061)
- Analyst Calls (5073)
- Autos (1473)
- Banking & Finance (3791)
- Bankruptcy (282)
- Buffett (339)
- Calendar (421)
- Casinos & Hotels (99)
- Commodities & Metals (1360)
- Consumer Product (795)
- Corporate Governance (1993)
- Dividends & Buybacks (925)
- Earnings (4146)
- Economy (3698)
- Editor's Picks (516)
- ETFs & Mutual Funds (822)
- General (3837)
- Healthcare (1434)
- Housing (1035)
- Industrials (630)
- Infrastructure (602)
- International Markets (4169)
- Internet (2194)
- IPOs & Secondaries (1651)
- Jobs (158)
- Labor (656)
- Media (4203)
- Mergers & Acquisitions (2226)
- Oil & Gas (2574)
- Personal Finance (305)
- Politics (823)
- Polls (34)
- Regulation (1162)
- Retail (2582)
- Rumors (1093)
- Services (297)
- Special Report (375)
- Technology (3824)
- Telecom & Wireless (1691)
- Transportation (581)
- Value Investing (763)
